Inozyme Pharma

Inozyme Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

We are a pioneering, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these metabolites. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.

Company Details

Employees
59
Founded
-
Address
321 Summer St,
Phone
+1 (857) 330-4340
Email
in****@****yme.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Boston, Massachusetts
Looking for a particular Inozyme Pharma employee's phone or email?

Inozyme Pharma Questions

News

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders - GlobeNewswire

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders GlobeNewswire

Inozyme Pharma Postpones 2025 Annual Meeting of Stockholders Amid BioMarin Acquisition Discussions - Quiver Quantitative

Inozyme Pharma Postpones 2025 Annual Meeting of Stockholders Amid BioMarin Acquisition Discussions Quiver Quantitative

INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients - Contemporary Pediatrics

INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients Contemporary Pediatrics

BioMarin to buy rare disease drugmaker Inozyme for $270M - BioPharma Dive

BioMarin to buy rare disease drugmaker Inozyme for $270M BioPharma Dive

BioMarin's $270M Acquisition Brings First-Ever Treatment for Fatal Childhood Bone Disease to Phase 3 - Stock Titan

BioMarin's $270M Acquisition Brings First-Ever Treatment for Fatal Childhood Bone Disease to Phase 3 Stock Titan

As M&A slows, Boston’s biotech sector stands out - Capital Analytics Associates

As M&A slows, Boston’s biotech sector stands out Capital Analytics Associates

BioMarin Expands Enzyme Expertise With $270M Inozyme Buy - BioSpace

BioMarin Expands Enzyme Expertise With $270M Inozyme Buy BioSpace

BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect in first M&A move of the Sabry era - Fierce Biotech

BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect in first M&A move of the Sabry era Fierce Biotech

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights GlobeNewswire

Data: 80% of INZ-701-treated infants with ENPP1 Deficiency survived past first year - Contemporary Pediatrics

Data: 80% of INZ-701-treated infants with ENPP1 Deficiency survived past first year Contemporary Pediatrics

Inozyme Pharma Reports Full Year 2024 Financial Results and - GlobeNewswire

Inozyme Pharma Reports Full Year 2024 Financial Results and GlobeNewswire

BioMarin agrees to acquire Inozyme for $270m - Pharmaceutical Technology

BioMarin agrees to acquire Inozyme for $270m Pharmaceutical Technology

FDA Grants Fast Track Designation to Inozyme Pharma’s INZ-701, a Treatment for Patients with ABCC6 Deficiency - Pharmaceutical Executive

FDA Grants Fast Track Designation to Inozyme Pharma’s INZ-701, a Treatment for Patients with ABCC6 Deficiency Pharmaceutical Executive

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - Yahoo Finance

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz Yahoo Finance

BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease - MedCity News

BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease MedCity News

BioMarin completes $270 million acquisition of Inozyme Pharma - Investing.com

BioMarin completes $270 million acquisition of Inozyme Pharma Investing.com

Katie Swanner - The Business Journals

Katie Swanner The Business Journals

Leerink bullish on BioMarin following Inozyme deal, expects additional BD - Yahoo Finance

Leerink bullish on BioMarin following Inozyme deal, expects additional BD Yahoo Finance

Inozyme Pharma Announces Positive Interim Data for INZ-701 - GlobeNewswire

Inozyme Pharma Announces Positive Interim Data for INZ-701 GlobeNewswire

Inozyme Pharma to Present at Upcoming Investor Conferences - Yahoo Finance

Inozyme Pharma to Present at Upcoming Investor Conferences Yahoo Finance

BioMarin Completes Acquisition of Inozyme Pharma for $270M - Contract Pharma

BioMarin Completes Acquisition of Inozyme Pharma for $270M Contract Pharma

Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire

Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders Business Wire

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks - Yahoo Finance

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks Yahoo Finance

Soojin Kim - The Business Journals

Soojin Kim The Business Journals

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A Genetic Engineering and Biotechnology News

BioMarin Acquires Inozyme for $270M, Gains Late-Stage Enzyme Therapy for Untreated Rare Disease - Stock Titan

BioMarin Acquires Inozyme for $270M, Gains Late-Stage Enzyme Therapy for Untreated Rare Disease Stock Titan

Dollar Stock Skyrockets 179% On BioMarin Takeover - Investor's Business Daily

Dollar Stock Skyrockets 179% On BioMarin Takeover Investor's Business Daily

BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha

BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) Seeking Alpha

Inozyme puts faith in Petra Duda as new CMO - The Pharma Letter

Inozyme puts faith in Petra Duda as new CMO The Pharma Letter

BioMarin buys Inozyme for $270 million - The Pharma Letter

BioMarin buys Inozyme for $270 million The Pharma Letter

Cooley, Goodwin Build BioMarin's $270M Inozyme Buy - Law360

Cooley, Goodwin Build BioMarin's $270M Inozyme Buy Law360

Ruth du Moulin - The Business Journals

Ruth du Moulin The Business Journals

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? - simplywall.st

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? simplywall.st

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 (NASDAQ:BMRN) - Seeking Alpha

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 (NASDAQ:BMRN) Seeking Alpha

BioMarin stock in focus on M&A deal with Inozyme (BMRN:NASDAQ) - Seeking Alpha

BioMarin stock in focus on M&A deal with Inozyme (BMRN:NASDAQ) Seeking Alpha

A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus - Pharma Voice

A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus Pharma Voice

INZ-701 Prevents Ectopic Tissue Calcification and Restores Bone Architecture and Growth in ENPP1-Deficient Mice - Wiley Online Library

INZ-701 Prevents Ectopic Tissue Calcification and Restores Bone Architecture and Growth in ENPP1-Deficient Mice Wiley Online Library

Inozyme Pharma Requests Nasdaq Delisting Post-Acquisition - TipRanks

Inozyme Pharma Requests Nasdaq Delisting Post-Acquisition TipRanks

Annexon, Inozyme, iTeos snag $564M in upsized IPOs - Fierce Biotech

Annexon, Inozyme, iTeos snag $564M in upsized IPOs Fierce Biotech

Sanofi, Novo back rare disease startup Inozyme in $49M round - Fierce Biotech

Sanofi, Novo back rare disease startup Inozyme in $49M round Fierce Biotech

Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies - GlobeNewswire

Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies GlobeNewswire

Top Inozyme Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant